logo
National Survey: Middle‑Income Americans Continue to Navigate Elevated Cost of Living and Economic Uncertainty

National Survey: Middle‑Income Americans Continue to Navigate Elevated Cost of Living and Economic Uncertainty

Business Wire13 hours ago
DULUTH, Ga.--(BUSINESS WIRE)--Middle‑income Americans are still adjusting to a higher cost of living and ongoing financial pressures, according to the latest Primerica ® U.S. Middle‑Income Financial Security Monitor™ (FSM™). The survey finds that 65% of middle-income Americans believe their income has not kept pace with rising expenses — a sentiment that has remained remarkably consistent for more than four years, highlighting the challenges families feel as prices outpace paychecks.
'Middle‑income families are making tough decisions every day to cover the essentials and save for the future, and it continues to shape how they perceive the overall economy, with many feeling less confident and more cautious about what lies ahead,' said Glenn J. Williams, CEO of Primerica. 'That makes it even more important for families to seek sound financial advice. A financial professional can help families find the money in their budgets, reprioritize expenses and build a realistic path to save for the future. Even starting with a small amount can make a significant difference over time.'
Middle‑income Americans continue to rate the economy poorly. More than three-quarters (80%) rate it negatively — a figure that has remained consistent over the past year. Amid ongoing economic uncertainty, a strong majority (83%) say they want to take steps to protect themselves financially for the long term — yet only 36% are actually doing so.
'The data shows how hard middle‑income families are working to stay afloat in an increasingly uncertain economic landscape,' said Amy Crews Cutts, Ph.D., CBE ®, economic consultant to Primerica. 'While sentiment shifts slightly from quarter to quarter, concerns about rising costs and financial stability remain top of mind for many households.'
Additional key findings from Primerica's Q2 2025 U.S. Middle-Income Financial Security Monitor™ (FSM™):
Middle-income Americans remain stressed at near record-high levels. A majority (61%) continue to report feeling 'stressed' about money and finances, with nearly half (45%) saying they feel 'discouraged.' Those who use a financial professional are less likely to say they are stressed and discouraged and more likely to say they are 'confident' or 'proud.'
Credit cards increasingly serve as a financial lifeline. About 39% of middle-income Americans say they have increased their credit card use, an 11‑point rise from Q1 2025 and the highest level recorded since early 2023. Meanwhile, just 32% pay their credit card balance in full each month, and 60% say their credit card debt has increased or remained the same.
Many feel underprepared, increasingly concerned about retirement. Nearly two-thirds (​​63%) do not believe they are saving enough to retire comfortably, and 39% aren't participating in an employer‑sponsored retirement or life insurance benefit, citing affordability as the primary barrier.
Saving for the future remains a challenge for most. Nearly three-quarters (71%) of middle-income Americans rate their ability to save for the future negatively, and nearly 40% report only having enough money to cover basic needs for one month or less should the primary breadwinner in their household lose their job.
Primerica Financial Security Monitor™ (FSM™) Topline Trends Data
Jun
2025
Mar
2025
Dec
2024
Sept
2024
Jun
2024
Mar
2024
Dec
2023
Sept
2023
Jun
2023
How would you rate the condition of your personal finances?
Share reporting 'Excellent' or 'Good.'
46%
48%
45%
44%
49%
50%
50%
49%
50%
Analysis: Respondents' assessments of their personal finances are down slightly from where they were a year ago.
Overall, would you say your income is…?
Share reporting 'Falling behind the cost of living'
65%
69%
65%
68%
66%
67%
68%
72%
71%
Share reporting 'Stayed about even with the cost of living'
24%
23%
29%
24%
26%
25%
24%
20%
22%
Analysis: Concern about meeting the increased cost of living remained steady.
And in the next year, do you think the American economy will be…?
Share reporting 'Worse off than it is now'
61%
76%
55%
25%
40%
46%
53%
56%
57%
Share reporting 'Uncertain'
4%
4%
9%
34%
19%
18%
9%
9%
9%
Analysis: The share of respondents expecting the economy to worsen over the next year has improved sharply since the previous poll in March 2025.
Do you have an emergency fund that would cover an expense of $1,000 or more (for example, if your car broke down or you had a large medical bill)?
Reporting 'Yes' responses
60%
64%
59%
61%
63%
62%
60%
62%
61%
Analysis: The percentage of Americans who have an emergency fund that would cover an expense of $1,000 or more has fallen since the previous survey.
How would you rate the economic health of your community?
Reporting 'Not so good' and 'Poor' responses
59%
66%
63%
63%
58%
60%
57%
55%
54%
Analysis: Respondents' rating of the economic health of their communities has stayed about the same over the past year.
How would you rate your ability to save for the future?
Reporting 'Not so good' and 'Poor' responses
71%
71%
71%
73%
68%
67%
73%
71%
71%
Analysis: A significant majority continue to feel it is difficult to save for the future.
In the past three months, has your credit card debt…?
Reporting 'Increased' responses
31%
31%
34%
35%
30%
34%
35%
34%
33%
Analysis: Credit card debt has remained about the same over the past year.
Expand
About Primerica's Middle-Income Financial Security Monitor™ (FSM™)
Since September 2020, the Primerica Financial Security Monitor™ has surveyed middle-income households quarterly to gain a clear picture of their financial situation, and it coincides with the release of the monthly HBI™ four times annually. Polling was conducted online from June 2-5, 2025. Using Dynamic Online Sampling, Change Research polled 1,241 adults nationwide with incomes between $30,000 and $130,000. Post-stratification weights were made on gender, age, race, education and Census region to reflect the population of these adults based on the five-year averages in the 2021 American Community Survey, published by the U.S. Census. The margin of error is 3.0%. For more information visit Primerica.com/public/financial-security-monitor.html.
About Primerica, Inc.
Primerica, Inc., headquartered in Duluth, GA, is a leading provider of financial products and services to middle-income households in North America. Independent licensed representatives educate Primerica clients about how to better prepare for a more secure financial future by assessing their needs and providing appropriate solutions through term life insurance, which we underwrite, and mutual funds, annuities and other financial products, which we distribute primarily on behalf of third parties. We insured over 5.5 million lives and had approximately 3.0 million client investment accounts on December 31, 2024. Primerica, through its insurance company subsidiaries, was the #3 issuer of Term Life insurance coverage in the United States and Canada in 2024. Primerica stock is included in the S&P MidCap 400 and the Russell 1000 stock indices and is traded on The New York Stock Exchange under the symbol 'PRI'. For more information, visit www.primerica.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Moon Surgical Launches Maestro™ Platform at Lee Health
Moon Surgical Launches Maestro™ Platform at Lee Health

Yahoo

time7 minutes ago

  • Yahoo

Moon Surgical Launches Maestro™ Platform at Lee Health

PARIS and SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- Moon Surgical, the leader in Physical AI for the operating room, today announced the successful launch of its Maestro™ Platform at Lee Health's Gulf Coast Medical Center in Fort Meyers, Florida, marking another milestone in the platform's growing adoption across the United States. Lee Health has already completed over 100 procedures using Maestro, including bariatric and general surgeries. Notably, the hospital reported: Zero adverse events No increase in operative time or length of stay, even in the initial cases Operational efficiencies which enable the reduction of one surgical technologist or advanced provider per case without compromising care In just the first 25 bariatric cases, Maestro helped Lee Health save the equivalent of 8.3 full working days of surgical tech time, demonstrating its impact on staffing efficiency and resource optimization. QUOTE: Juan Ibarra, M.D - Robotic Surgery Program Manager, Lee Heath: "We're proud to be among the early U.S. institutions to adopt the Maestro Platform. We've completed over 100 procedures, each one delivering excellent clinical and operational outcomes. For surgeons who prefer traditional laparoscopy, Maestro offers a smart and reliable assistant without changing their preferred surgical approach. We are proud at Lee Health to be setting the pace with technology that improves efficiency, maintains safety, and supports our teams." "The program launch and partnership with Lee Health is a great example of how Maestro is defining a new category of MIS." said Anne Osdoit, Moon Surgical CEO. "Maestro has quickly delivered consistent and scalable positive impact for surgeons, their teams, the hospital system and its patients." The launch at Lee Health comes on the heels of a recent announcement on the rapidly broadening usage of the Maestro™ System, which has now supported over 1,600 procedures worldwide, including 1,400 in the past year alone, across 60 different types of minimally invasive surgeries. Maestro's growing adoption highlights its adaptability across specialties and its value in high-volume outpatient care. Moon Surgical continues to redefine the operating room with Maestro, a surgical technology platform powered by Physical AI. Designed to enhance human performance, Maestro supports surgical teams with adaptability, control, and efficient integration into existing workflows. About Moon Surgical Moon Surgical is transforming the operating room with Physical AI, seamlessly integrating intelligence and robotics to elevate the capabilities of surgical teams. The Maestro System represents a new category of minimally invasive surgery—expanding the scale at which robotics are delivered into the operating rooms. Instinctive, collaborative, and cost-effective, Maestro empowers teams to deliver exceptional care with greater adaptability and control. Moon Surgical. Inspiring and Innovating the Art of Surgery. Moon Surgical® and Maestro® are registered trademarks of Moon Surgical, SAS View original content to download multimedia: SOURCE Moon Surgical

Number of Canadians with favourable view of U.S. has fallen, poll suggests
Number of Canadians with favourable view of U.S. has fallen, poll suggests

Yahoo

time9 minutes ago

  • Yahoo

Number of Canadians with favourable view of U.S. has fallen, poll suggests

WASHINGTON — Amid months of tariffs and taunts from U.S. President Donald Trump, a new poll suggests the percentage of Canadians who have a favourable view of the United States has fallen and is now on par with the number who think positively about China. The survey by the Pew Research Center suggests one-third of Canadians — 34 per cent — now have a favourable view of the United States. It marks a 20 percentage point decrease from last year. The same percentage of Canadians had favourable views of China — a 13 point increase. "For the last few years … many people have preferred the U.S. to China by a sizable margin,' said Laura Silver, associate director of global attitudes research at the Washington-based research centre. Now, she said, "there's no daylight between the two." Pew polled people in 25 countries and the survey found positive views of China increased in more than half the nations. There was also an increase in people who viewed Chinese President Xi Jinping favourably. "This is the first real tick up that we've seen that we would describe as an increase across the board," Silver said. Trump returned to the White House with an agenda to realign global trade and upend geopolitics by targeting friend and foe alike. Critics of Trump's tactics have said the ongoing instability will push countries to form closer ties with China. Canada was an early target with Trump repeatedly calling former prime minister Justin Trudeau "governor" and insisting Canada should become a U.S. state. The president hit Canada and Mexico with duties he linked to fentanyl trafficking in March, only to walk back the tariffs for goods that comply with the Canada-U.S.-Mexico Agreement on trade a few days later. Trump took his trade war to the world in April with so-called "reciprocal" tariffs but paused the devastating duties a few hours later saying it would give time for countries to make a deal with America. He kept in place a 10 per cent tariff for most countries. China was hit by the hardest duties, prompting a brief but escalated tariff standoff between the world's two largest economies. The U.S. president has been sending out letters to nations suggesting they will be hit with high duty rates if no deal is made by Aug. 1. Trump did go ahead with specific tariffs targeting steel, aluminum and automobile imports, with copper duties also set to come into place on Aug. 1. Pew, a non-partisan think tank, surveyed 28,333 adults across 24 countries – not including the United States – from Jan. 8 to April 26 by phone, online and in person. The centre also surveyed 3,605 Americans from March 24 to March 30 by phone, online and in person. The poll reports 26 per cent of all people surveyed said they had confidence in the Chinese president, while 22 per cent said the same for Trump. "That reflects both a rising view of Xi and a quite dramatically negative view of Trump," Silver said. The changing views were especially stark in Mexico, where 45 per cent of people said it's more important for their country to have strong economic ties with China than with the U.S. — up from 37 per cent in 2019 and 15 per cent in 2015. Canada's relationship with China was roiled during the first Trump administration when in 2018 Canadians Michael Spavor and Michael Kovrig were taken into custody in China. It followed the arrest of Huawei's chief financial officer Meng Wanzhou in British Columbia at the request of the United States. Silver said the 2025 polling is the first time there hasn't been a wide gap in how Canadians view the world's two largest economies since the relationship with China took a "nosedive." The Pew Research Center survey found the share of Canadians who said the U.S. was more important for economic ties had dropped to 67 per cent from 87 per cent in 2019. "Now, while it's still a majority, it's down more than 20 percentage points with a corresponding rise in the share who prefer China," Silver said. This report by The Canadian Press was first published July 15, 2025. Kelly Geraldine Malone, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer's Disease and Related Dementias
C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer's Disease and Related Dementias

Business Wire

time17 minutes ago

  • Business Wire

C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer's Disease and Related Dementias

ST. LOUIS--(BUSINESS WIRE)-- C2N Diagnostics, LLC, a pioneer in advanced diagnostic testing for brain health, announces the launch of two new highly anticipated plasma assays for Research Use Only: C2N eMTBR-tau243 and C2N %p-tau MAA. 'Our introduction of the C2N eMTBR-tau243 blood test and the C2N %p-tau MAA demonstrates C2N's commitment to clinically-relevant innovations and advancing brain health diagnostics," says C2N CEO and President Dr. Joel Braunstein. C2N eMTBR-tau243 (endogenous Microtubule Binding Region) is a unique blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer's disease. C2N cites research that says this may provide the potential to improve the diagnostic evaluation of Alzheimer's pathology in clinical trials, supporting essential disease staging, predicting disease progression and response to treatment, and monitoring treatment efficacy. This new plasma assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by C2N nearly two years ago and is available for Research Use Only. C2N obtained the exclusive rights for these technologies from the Bateman Lab at WashU Medicine. With funding from the GHR Foundation, the C2N team optimized and industrialized these assays using rigorous analytical methods to bring them to their current state. The company aims to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future. C2N Increases Diagnostic Power With C2N %p-tau MAA C2N is also launching a novel p-tau multi-analyte assay (MAA). This assay uses high-resolution mass spectrometry (LC-MS/MS) to precisely quantitate six analytes related to phosphorylated and nonphosphorylated forms of tau (%p-tau181, %p-tau205 and %p-tau217). The C2N %p-tau MAA measures multiple phosphorylated tau forms from a single sample and, therefore, enables greater efficiencies. This test is likewise available for Research Use Only. C2N's LC-MS/MS methodologies enable a ratio of phosphorylated tau divided by non-phosphorylated tau (%p-tau) that previously has been shown to mitigate for confounding factors such as age and medical comorbidities like kidney disease. The Journal of the American Medical Association (JAMA) published a large clinical study that found C2N's PrecivityAD2™ test accuracy was not impacted in the primary care arm of the study despite having patients of older age and with higher prevalence of comorbidities. The company believes the C2N %p-tau MAA and C2N eMTBR-tau243 assays will play a key role in biopharma clinical trials, enabling better assessment of Alzheimer's disease pathology and supporting a precision medicine approach to novel treatment strategies. The assays will cover both early-stage and late-stage tau pathology identification, providing a robust marker for disease identification, staging, and stratification. 'Our introduction of the C2N eMTBR-tau243 blood test and the C2N %p-tau MAA demonstrates C2N's commitment to clinically-relevant innovations and advancing brain health diagnostics, first as Research Use Only tools and then in the form of clinical diagnostic tests,' says C2N CEO and President Dr. Joel Braunstein. 'Patients and families worried about Alzheimer's disease are pressing on the entire healthcare sector for a clearer picture of Alzheimer's disease pathology. We are responding, first for researchers and then for the broader global healthcare provider community.' The Precivity™ line of blood tests currently available clinically to aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions are: PrecivityAD®, PrecivityAD2™, and Precivity-AopE™. About C2N Diagnostics, LLC C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N's high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 150 Alzheimer's disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer's disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer's Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories, and Unilabs. Over 50,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review. The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer's Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer's Association. For more information visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store